An Open-Label, Multicenter, Phase 1 Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Intravenous Doses of Inhibrx rhAAT-Fc (INBRX-101) in Adults with Alpha-1 Antitrypsin Deficiency (AATD)
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Conditions: Alpha-1 Antitrypsin Deficiency (AATD)
Age: Between 18 - 70 Years
Gender: Male or Female
AATD diagnosis, willing to undergo 2 bronchoscopies
Willing to hold current AATD treatment until study ends (about 5 months).
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required